Dingens, Adam S. http://orcid.org/0000-0001-9603-9409
Crawford, Katharine H. D.
Adler, Amanda
Steele, Sarah L.
Lacombe, Kirsten
Eguia, Rachel
Amanat, Fatima http://orcid.org/0000-0002-8029-8227
Walls, Alexandra C.
Wolf, Caitlin R.
Murphy, Michael
Pettie, Deleah http://orcid.org/0000-0002-5477-7195
Carter, Lauren
Qin, Xuan
King, Neil P.
Veesler, David http://orcid.org/0000-0002-6019-8675
Krammer, Florian http://orcid.org/0000-0003-4121-776X
Dickerson, Jane A.
Chu, Helen Y.
Englund, Janet A.
Bloom, Jesse D. http://orcid.org/0000-0003-1267-3408
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI140891, HHSN272201700059C, F30AI149928, HHSN272201400008C, 75N93019C00051)
Bill and Melinda Gates Foundation (OPP1156262)
Howard Hughes Medical Institute
Article History
Received: 26 June 2020
Accepted: 7 August 2020
First Online: 1 September 2020
Competing interests
: H.Y.C. is a consultant for Merck and Glaxo Smith Kline and receives research funding from Sanofi Pasteur, outside of the submitted work. N.P.K. is a co-founder, shareholder, and chair of the scientific advisory board of Icosavax, Inc. Mount Sinai has licensed serological assays to commercial entities and has filed for patent protection for serological assays. J.A.E. is a consultant for Sanofi Pasteur and Meissa Vaccines. The remaining authors declare no competing interests.